Back to School: How biopharma can reboot drug development. Access exclusive analysis here

4Q milestones

4Q milestones

Company Product Standard indication Event Milestone
Accentia (ABPI) SinuNase Sinusitis Ph III data YE07
Acusphere (ACUS)/Nycomed Imagify (AI-700) Cardiovascular Submit NDA 4Q07
Adams Respiratory (ARXT) Extended-release guaifenesin combination Cough PDUFA date Oct. 27
Adv Life Sci (ADLS) Cethromycin Pneumonia Ph III data; submit NDA November; YE07
Aeterna Zentaris (TSX:AEZ; AEZS)/Ardana (LSE:ARA) ARD-07 (Formerly EP-1572) Growth hormone deficiency Ph III data; submit NDA November; YE07
AMAG Pharma (AMAG) Ferumoxytol Anemia Submit NDA 4Q07
Amgen (AMGN) AMG 531 Idiopathic thrombocytopenic purpura (ITP) US and EU regulatory submissions YE07
Amylin (AMLN)/Eli Lilly (LLY)/Alkermes (ALKS) Exenatide

Read the full 985 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers